Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Beyer

Showing results (171-180 of 225) with videos related to

Pageof 23
Sort By:
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 5, 2023
Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trialUrsula Rauch-Kröhnert, Marianna Puccini, Marius Placzek, et al.
Thrombosis and Haemostasis|March 25, 2016
Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE TrialStefano Barco, Mareike Lankeit, Harald Binder, et al.
JACC. Advances|June 28, 2024
Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney DiseaseReinhold Kreutz, Gilbert Deray, Jürgen Floege, et al.
Journal of Clinical Medicine|January 11, 2024
Clinical Course and Management of Patients with Emergency Surgery Treated with Direct Oral Anticoagulants or Vitamin K Antagonists-Results of the German Prospective RADOA-RegistryJana Last, Eva Herrmann, Ingvild Birschmann, et al.
Journal of the American College of Cardiology|November 25, 2017
Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced ThrombocytopeniaMarc Schindewolf, Julia Steindl, Jan Beyer-Westendorf, et al.
Thrombosis Research|April 8, 2014
Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry studyMarc Schindewolf, Julia Steindl, Jan Beyer-Westendorf, et al.
Thrombosis and Haemostasis|September 2, 2016
Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysisY Whitney Cheung, Saskia Middeldorp, Martin H Prins, et al.
Deutsches Arzteblatt International|July 2, 2020
Severe Hemorrhage Associated With Oral AnticoagulantsEdelgard Lindhoff-Last, Eva Herrmann, Simone Lindau, et al.
Brain and Behavior|April 29, 2024
Total intracranial hemorrhage volume measurement summating all compartments best in traumatic and nontraumatic intracranial bleedingMacKenzie Horn, Ankur Banerjee, Linda Kasickova, et al.
Stroke|October 14, 2021
Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual CareHagen B Huttner, Stefan T Gerner, Joji B Kuramatsu, et al.
Pageof 23

Showing results (171-180 of 225) with videos related to

Sort By:
Pageof 23
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 5, 2023
Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trialUrsula Rauch-Kröhnert, Marianna Puccini, Marius Placzek, et al.
Thrombosis and Haemostasis|March 25, 2016
Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE TrialStefano Barco, Mareike Lankeit, Harald Binder, et al.
JACC. Advances|June 28, 2024
Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney DiseaseReinhold Kreutz, Gilbert Deray, Jürgen Floege, et al.
Journal of Clinical Medicine|January 11, 2024
Clinical Course and Management of Patients with Emergency Surgery Treated with Direct Oral Anticoagulants or Vitamin K Antagonists-Results of the German Prospective RADOA-RegistryJana Last, Eva Herrmann, Ingvild Birschmann, et al.
Journal of the American College of Cardiology|November 25, 2017
Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced ThrombocytopeniaMarc Schindewolf, Julia Steindl, Jan Beyer-Westendorf, et al.
Thrombosis Research|April 8, 2014
Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry studyMarc Schindewolf, Julia Steindl, Jan Beyer-Westendorf, et al.
Thrombosis and Haemostasis|September 2, 2016
Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysisY Whitney Cheung, Saskia Middeldorp, Martin H Prins, et al.
Deutsches Arzteblatt International|July 2, 2020
Severe Hemorrhage Associated With Oral AnticoagulantsEdelgard Lindhoff-Last, Eva Herrmann, Simone Lindau, et al.
Brain and Behavior|April 29, 2024
Total intracranial hemorrhage volume measurement summating all compartments best in traumatic and nontraumatic intracranial bleedingMacKenzie Horn, Ankur Banerjee, Linda Kasickova, et al.
Stroke|October 14, 2021
Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual CareHagen B Huttner, Stefan T Gerner, Joji B Kuramatsu, et al.
Pageof 23